Diet and irritable bowel syndrome

Current Opinion in Gastroenterology

Volumn 31, Issue 2, 2015, Pages 166-171

  Thomas, Anusha ^a   Quigley, Eamonn M M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Diet; FODMAPs; Gluten; Irritable bowel syndrome; Probiotics

Indexed keywords

BULKING AGENT; DISACCHARIDE; GLUTEN; MONOSACCHARIDE; OLIGOSACCHARIDE; PEPPERMINT OIL; POLYOL; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; VEGETABLE OIL;

DIET; DIETARY FIBER; FOOD; HUMAN; IRRITABLE COLON; META ANALYSIS (TOPIC); NONHUMAN; REVIEW; SYSTEMATIC REVIEW (TOPIC); DIET THERAPY; GLUTEN FREE DIET; IMMUNOLOGY; PRACTICE GUIDELINE;

CALCIUM CHANNEL BLOCKERS; DIET, GLUTEN-FREE; HUMANS; IRRITABLE BOWEL SYNDROME; PLANT OILS; PRACTICE GUIDELINES AS TOPIC; PROBIOTICS;

EID: 84922760223     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000158     Document Type: Review

References (54)

1. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130:1480-1491.
2. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 2014; 40:1023-1034.
3. Huang H, Taylor DC, Carson RT, et al. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States. J Med Econ 2014. [Epub ahead of print]
4. Buono JL, Tourkodimitris S, Sarocco P, et al. Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, place-bo-controlled phase 3 trials. Am Health Drug Benefits 2014; 7:289-297.
5. Hou X, Chen S, Zhang Y, et al. Quality of life in patients with irritable bowel syndrome (IBS), assessed using the IBS-quality of life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig 2014; 34:783-793.
6. Bellini M, Gambaccini D, Stasi C, et al. Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol 2014; 20:8807-8820.
7. Stasi C, Rosselli M, Bellini M, et al. Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol 2012; 47:1177-1185.
8. Buckley MM, O'Mahony SM, O'Malley D. Convergence of neuro-endocrineimmune pathways in the pathophysiology of irritable bowel syndrome. World J Gastroenterol 2014; 20:8846-8858.
9. Al Omran Y, Aziz Q. The brain-gut axis in health and disease. Adv Exp Med Biol 2014; 817:135-153.
10. Simré n M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome Foundation report. Gut 2013; 62:159-176.
11. Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 2014; 20:8886-8897.
12. Hyland NP, Quigley EM, Brint E. Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol 2014; 20:8859-8866.
13. Buckley MM, O'Halloran KD, Rae MG, et al. Modulation of enteric neurons by interleukin-6 and corticotropin-releasing factor contributes to visceral hypersensitivity and altered colonic motility in a rat model of irritable bowel syndrome. J Physiol 2014; 592:5235-5250.
14. Wall GC, Bryant GA, Bottenberg MM, et al. Irritable bowel syndrome: a concise review of current treatment concepts. World J Gastroenterol 2014; 20:8796-8806.
15. Böhn L, Störsrud S, Törnblom H, et al. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol 2013; 108:634-641.
16. Cuomo R, Andreozzi P, Zito FP, et al. Irritable bowel syndrome and food interaction. World J Gastroenterol 2014; 20:8837-8845.
17. Posserud I, Strid H, Störsrud S, et al. Symptom pattern following a meal challenge test in patients with irritable bowel syndrome and healthy controls. United Eur Gastroenterol J 2013; 1:358-367.
18. Shekhar C, Monaghan PJ, Morris J, et al. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin. Gastroenterology 2013; 145:749-757.
19. Hayes P, Corish C, O'Mahony E, Quigley EM. A dietary survey of patients with irritable bowel syndrome. J Hum Nutr Diet 2014; 27 (Suppl 2):36-47.
20. Hayes PA, Fraher MH, Quigley EM. Irritable bowel syndrome: the role of food in pathogenesis and management. Gastroenterol Hepatol (N Y) 2014; 10:164-174.
21. Fritscher-Ravens A, Schuppan D, Ellrichmann M, et al. Confocal endomicroscopy reveals food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 2014; 147:1012-1020.
22. Wahnschaffe U, Ullrich R, Riecken EO, Schulzke JD. Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. Gastroenterology 2001; 121:1329-1338.
23. Kennedy PJ, Allen AP, O'Neill A, et al. Acute tryptophan depletion reduces kynurenine levels: implications for treatment of impaired visuospatial memory performance in irritable bowel syndrome. Psychopharmacology (Berl) 2014. [Epub ahead of print]
24. Ford AC, Moayyedi P, Lacy BE, et al. Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014; 109 (Suppl 1):S2-S26.
25. Guo YB, Zhuang KM, Kuang L, et al. Association between diet and lifestyle habits and irritable bowel syndrome: a case-control study. Gut Liver 2014. [Epub ahead of print]
26. Power SE, O'Toole PW, Stanton C, et al. Intestinal microbiota, diet and health. Br J Nutr 2014; 111:387-402.
27. Clarke SF, Murphy EF, O'Sullivan O, et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut 2014; 63:1913-1920.
28. Moayyedi P,Quigley EM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109:1367-1374.
29. Murray K, Wilkinson-Smith V, Hoad C, et al. Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol 2014; 109:110-119.
30. Halmos EP, Christophersen CT, Bird AR, et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 2015; 64:93-100.
31. Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010; 25:1366-1373.
32. Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146:67-75.
33. Staudacher HM, Lomer MC, Anderson JL, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 2012; 142:1510-1518.
34. Berg LK, Fagerli E, Martinussen M, et al. Effect of fructose-reduced diet in patients with irritable bowel syndrome, and its correlation to a standard fructose breath test. Scand J Gastroenterol 2013; 48:936-943.
35. Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut 2013; 62:43-52.
36. Catassi C, Bai JC, Bonaz B, et al. Non-celiac gluten sensitivity: the new frontier of gluten related disorders. Nutrients 2013; 5:3839-3853.
37. Sainsbury A, Sanders DS, Ford AC. Prevalence of irritable bowel syndrometype symptoms in patients with celiac disease: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11:359-365.
38. Card TR, Siffledeen J, West J, Fleming KM. An excess of prior irritable bowel syndrome diagnoses or treatments in Celiac disease: evidence of diagnostic delay. Scand J Gastroenterol 2013; 48:801-807.
39. Shayesteh AA, Hajiani E, Hashemi SJ, et al. Prevalence of celiac disease in Iranian patients with irritable bowel syndrome: a cross-sectional study. J Dig Dis 2014; 15:12-17.
40. Cristofori F, Fontana C, Magistá A, et al. Increased prevalence of celiac disease among pediatric patients with irritable bowel syndrome: a 6-year prospective cohort study. JAMA Pediatr 2014; 168:555-560.
41. Lu W, Gwee KA, Siah KT, et al. Prevalence of antideamidated gliadin peptide antibodies in Asian patients with irritable bowel syndrome. J Neurogastroenterol Motil 2014; 20:236-241.
42. Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011; 106:508-514.
43. Carroccio A, Mansueto P, Iacono G, et al. Nonceliac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol 2012; 107:1898-1906.
44. Vazquez Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 2013; 144:903-911.
45. Rodrigo L, Blanco I, Bobes J, de Serres FJ. Effect of one year of a gluten free diet on the clinical evolution of irritable bowel syndrome plus fibromyalgia in patients with associated lymphocytic enteritis: a case controlled study. Arthritis Res Ther 2014; 16:421.
46. Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported nonceliac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145:320-328.
47. Bucci C, Zingone F, Russo I, et al. Gliadin does not induce mucosal inflammation or basophil activation in patients with nonceliac gluten sensitivity. Clin Gastroenterol Hepatol 2013; 11:1294-1299.
48. Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 2014; 20:8886-8897.
49. Quigley EM, Shanahan F. The future of probiotics for disorders of the brain-gut axis. Adv Exp Med Biol 2014; 817:417-432.
50. Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD: challenges and controversies. Gastroenterology 2014; 146:1554-1563.
51. Ng SC, Lam EF, Lam TT, et al. Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome. J Gastroenterol Hepatol 2013; 28:1624-1631.
52. Yoon JS, Sohn W, Lee OY, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol 2014; 29:52-59.
53. FordAC,QuigleyEM, LacyBE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014; 109:1547-1561.
54. Mullin GE, Shepherd SJ, Chander Roland B, et al. Irritable bowel syndrome: contemporary nutrition management strategies. JPEN J Parenter Enteral Nutr 2014; 38:781-799.